ClearPoint Neuro (NASDAQ:CLPT) Director Timothy Richards Sells 5,415 Shares of Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Director Timothy Richards sold 5,415 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $12.17, for a total transaction of $65,900.55. Following the completion of the transaction, the director owned 87,198 shares in the company, valued at $1,061,199.66. The trade was a 5.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

ClearPoint Neuro Stock Performance

NASDAQ:CLPT opened at $12.37 on Wednesday. ClearPoint Neuro, Inc. has a 1 year low of $8.27 and a 1 year high of $30.10. The firm’s fifty day simple moving average is $10.73 and its 200 day simple moving average is $12.54. The company has a current ratio of 5.79, a quick ratio of 4.88 and a debt-to-equity ratio of 2.63. The firm has a market capitalization of $370.98 million, a PE ratio of -12.25 and a beta of 1.31.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). The company had revenue of $12.13 million during the quarter, compared to analyst estimates of $11.97 million. ClearPoint Neuro had a negative return on equity of 140.96% and a negative net margin of 71.57%. On average, sell-side analysts anticipate that ClearPoint Neuro, Inc. will post -1.05 EPS for the current year.

Institutional Trading of ClearPoint Neuro

Several institutional investors have recently made changes to their positions in CLPT. Millennium Management LLC boosted its position in shares of ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after acquiring an additional 452,043 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of ClearPoint Neuro by 98.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after acquiring an additional 127,823 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of ClearPoint Neuro by 35.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,790 shares of the company’s stock valued at $392,000 after acquiring an additional 8,581 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of ClearPoint Neuro during the 2nd quarter valued at about $35,000. Finally, Rhumbline Advisers acquired a new stake in shares of ClearPoint Neuro during the 2nd quarter valued at about $450,000. 30.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Monday, April 20th. Stifel Nicolaus began coverage on shares of ClearPoint Neuro in a research report on Friday, May 8th. They set a “buy” rating and a $16.00 target price on the stock. Finally, B. Riley Financial lifted their target price on shares of ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $18.00.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.